HK1061403A1 - ANTIBODIES TO HUMAN IL-1ß - Google Patents

ANTIBODIES TO HUMAN IL-1ß

Info

Publication number: HK1061403A1
Authority: HK; Hong Kong
Prior art keywords: antibodies; human
Prior art date: 2000-08-22

Application number

HK04103018.8A

Other languages

English (en)

Inventor

Hermann Gram

Franco E Dipadova

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2004-04-29

Publication date

2004-09-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1061403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-29 Application filed by Novartis Ag filed Critical Novartis Ag

2004-09-17 Publication of HK1061403A1 publication Critical patent/HK1061403A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Hematology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)

HK04103018.8A 2000-08-22 2004-04-29 ANTIBODIES TO HUMAN IL-1ß HK1061403A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0020685.4A GB0020685D0 (en)	2000-08-22	2000-08-22	Organic compounds
PCT/EP2001/009588 WO2002016436A2 (en)	2000-08-22	2001-08-20	ANTIBODIES TO HUMAN IL-1$g(b)

Publications (1)

Publication Number	Publication Date
HK1061403A1 true HK1061403A1 (en)	2004-09-17

Family

ID=9898090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK04103018.8A HK1061403A1 (en)	2000-08-22	2004-04-29	ANTIBODIES TO HUMAN IL-1ß

Country Status (37)

Country	Link
US (3)	US7446175B2 (no)
EP (1)	EP1313769B2 (no)
JP (2)	JP4271936B2 (no)
KR (2)	KR100910789B1 (no)
CN (1)	CN100547003C (no)
AR (1)	AR035581A1 (no)
AT (1)	ATE396206T1 (no)
AU (2)	AU9549001A (no)
BE (1)	BE2009C057I2 (no)
BR (1)	BR0113420A (no)
CA (1)	CA2420231C (no)
CY (2)	CY1108779T1 (no)
CZ (1)	CZ304470B6 (no)
DE (2)	DE60134148D1 (no)
DK (1)	DK1313769T4 (no)
EC (1)	ECSP034490A (no)
ES (1)	ES2305110T5 (no)
FR (1)	FR09C0062I2 (no)
GB (1)	GB0020685D0 (no)
HK (1)	HK1061403A1 (no)
HU (2)	HU228159B1 (no)
IL (2)	IL154465A0 (no)
LU (1)	LU91624I2 (no)
MX (1)	MXPA03001590A (no)
MY (1)	MY130248A (no)
NL (1)	NL300427I2 (no)
NO (3)	NO332609B1 (no)
NZ (2)	NZ524199A (no)
PE (1)	PE20020319A1 (no)
PL (1)	PL212480B1 (no)
PT (1)	PT1313769E (no)
RU (1)	RU2286351C2 (no)
SI (1)	SI1313769T2 (no)
SK (1)	SK288089B6 (no)
TW (1)	TWI321568B (no)
WO (1)	WO2002016436A2 (no)
ZA (1)	ZA200301275B (no)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2426710A1 (en) *	2000-11-08	2002-10-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
EA033750B1 (ru)	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
CN1780855B (zh) *	2003-01-24	2011-03-30	应用分子进化公司	人IL-1β拮抗剂
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
US20040224893A1 (en) *	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) *	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
DK1720893T3 (en)	2004-02-26	2014-11-24	Baylor Res Inst	COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
US7566772B2 (en) *	2005-01-26	2009-07-28	Amgen Fremont Inc.	Antibodies against interleukin-1β
AU2012213934B9 (en) *	2005-01-26	2013-07-25	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
GB0509512D0 (en) *	2005-05-10	2005-06-15	Novartis Ag	Organic compounds
KR101502920B1 (ko) *	2005-06-21	2015-03-17	조마 (유에스) 엘엘씨	ＩＬ-１β 결합성 항체 및 그의 단편
JP2009511545A (ja) *	2005-10-14	2009-03-19	ノボ・ノルデイスク・エー／エス	Ｉｌ−１インヒビターを使用する糖尿病の治療
DK2848258T3 (en) *	2005-10-26	2018-03-19	Novartis Ag	Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
KR20110079922A (ko) *	2006-04-14	2011-07-11	노파르티스 아게	안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US7695718B2 (en) *	2006-12-20	2010-04-13	Xoma Technology Ltd.	Methods for the treatment of IL-1β related diseases
CL2008001071A1 (es) *	2007-04-17	2009-05-22	Smithkline Beecham Corp	Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
CN104873972A (zh)	2007-05-29	2015-09-02	诺华股份有限公司	抗IL-1β治疗的新适应症
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
ES2527326T3 (es) *	2007-12-20	2015-01-22	Xoma (Us) Llc	Métodos para el tratamiento de la gota
US9029508B2 (en)	2008-04-29	2015-05-12	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) *	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
WO2009149185A2 (en)	2008-06-03	2009-12-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
ES2398693T3 (es) *	2008-06-06	2013-03-21	Xoma Technology Ltd.	Métodos para el tratamiento de la artritis reumatoide
CN102149825B (zh)	2008-07-08	2015-07-22	Abbvie公司	前列腺素e2双重可变结构域免疫球蛋白及其用途
EP2341935A4 (en)	2008-09-05	2012-07-25	Xoma Technology Ltd	METHODS FOR IMPROVING BETA CELL FUNCTION
CN102257007A (zh) *	2008-10-20	2011-11-23	雅培制药有限公司	与il-18结合的抗体及其纯化方法
US8298533B2 (en) *	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
US20130122008A1 (en) *	2009-05-06	2013-05-16	Novartis Ag	Anti-IL 1- ß Antibody Combination Therapy
US8389474B1 (en) *	2009-07-14	2013-03-05	Alan Anson Wanderer	Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
CN102612524A (zh) *	2009-09-01	2012-07-25	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
TW201119676A (en)	2009-10-15	2011-06-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
KR101985153B1 (ko)	2009-10-26	2019-05-31	에프. 호프만-라 로슈 아게	글리코실화된 면역글로불린의 제조 방법
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011140522A1 (en)	2010-05-07	2011-11-10	Xoma Technology Ltd.	METHODS FOR THE TREATMENT OF IL-1β RELATED CONDITIONS
TW201206473A (en)	2010-08-03	2012-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
AU2011293253B2 (en)	2010-08-26	2014-12-11	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
JP2014519480A (ja)	2011-04-15	2014-08-14	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	癌で使用される抗ｉｌ−１ｒ１阻害物質
EP2731971A1 (en)	2011-07-12	2014-05-21	Universität Zürich	MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014007253A2 (pt)	2011-09-30	2017-03-28	Novartis Ag	uso de anticorpos que se ligam a il-1beta
WO2013082282A1 (en)	2011-12-02	2013-06-06	lNOVARTIS AG	Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
JP6342812B2 (ja) *	2011-12-14	2018-06-13	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	鉄関連障害を診断および治療するための組成物および方法
WO2013087911A1 (en)	2011-12-16	2013-06-20	Synthon Biopharmaceuticals B.V.	Compounds and methods for treating inflammatory diseases
US20150017157A1 (en)	2011-12-19	2015-01-15	Xoma (Us) Llc	Methods for treating acne
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
SG10201708562VA (en)	2012-02-13	2017-12-28	Agency Science Tech & Res	IL-1β Neutralizing Human Monoclonal Antibodies
CN103588878A (zh) *	2012-08-15	2014-02-19	江苏泰康生物医药有限公司	一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
SG11201503412RA (en)	2012-11-01	2015-05-28	Abbvie Inc	Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
PL2914287T3 (pl)	2012-11-05	2020-09-07	Delenex Therapeutics Ag	Elementy wiążące się z il-1 beta
AU2013344796B2 (en)	2012-11-16	2016-11-10	Novartis Ag	Use of IL-1 beta binding antibodies for treating peripheral arterial disease
ES2895848T3 (es)	2012-12-17	2022-02-22	Cell Medica Inc	Anticuerpos contra IL-1 beta
UY35195A (es)	2012-12-18	2014-07-31	Novartis Ag	Composiciones y metodos para proteinas de accion prolongada
US9062108B2 (en)	2013-03-15	2015-06-23	Abbvie Inc.	Dual specific binding proteins directed against IL-1 and/or IL-17
WO2015083120A1 (en)	2013-12-04	2015-06-11	Novartis Ag	USE OF IL-1β BINDING ANTIBODIES
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
US20170327553A1 (en)	2014-06-25	2017-11-16	Novartis Ag	Compositions and methods for long acting proteins
WO2016008851A1 (en) *	2014-07-14	2016-01-21	Boehringer Ingelheim International Gmbh	Anti-il-1b antibodies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en)	2014-10-14	2016-04-21	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
WO2016075037A1 (en)	2014-11-10	2016-05-19	F. Hoffmann-La Roche Ag	Bispecific antibodies and methods of use in ophthalmology
JP2017534644A (ja)	2014-11-10	2017-11-24	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ａｎｇ２抗体及び使用方法
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
CA2988055A1 (en)	2015-06-04	2016-12-08	Novartis Ag	Use of il-1 beta binding antibodies to treat peripheral arterial disease
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh)	2015-07-29	2021-12-24	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
KR20180088907A (ko)	2015-12-17	2018-08-07	노파르티스 아게	Pd-1에 대한 항체 분자 및 그의 용도
EP3426775A1 (en)	2016-03-10	2019-01-16	Novartis AG	Chemically modified messenger rna's
US20210292404A1 (en)	2016-07-21	2021-09-23	Novartis Ag	Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
CA3044526A1 (en)	2016-12-07	2018-06-14	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
EP3554343A1 (en)	2016-12-14	2019-10-23	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
JP2020524694A (ja)	2017-06-22	2020-08-20	ノバルティスアーゲー	がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
US20200158716A1 (en) *	2017-07-17	2020-05-21	Massachusetts Institute Of Technology	Cell atlas of healthy and diseased barrier tissues
WO2019038740A1 (en)	2017-08-25	2019-02-28	Novartis Ag	USE OF CANAKINUMAB
BR112020004903A2 (pt)	2017-09-13	2020-09-15	Novartis Ag	uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
US20200277378A1 (en)	2017-11-16	2020-09-03	Novartis Ag	Combination therapies
KR20210008847A (ko) *	2018-05-09	2021-01-25	노파르티스 아게	카나키누맙의 용도
SG11202010579XA (en)	2018-06-01	2020-12-30	Novartis Ag	Binding molecules against bcma and uses thereof
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) *	2018-07-25	2020-01-29	Robert Wotherspoon Hugh	IL-1ß binding antibody
CN110818793A (zh) *	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en)	2018-08-24	2020-02-27	Novartis Ag	Treatment comprising il-1βeta binding antibodies and combinations thereof
US11976115B2 (en) *	2018-11-07	2024-05-07	Zeda Biopharmaceuticals, Inc.	Antibody binding to human IL-1β, preparation method therefor and use thereof
EP3883635A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
CN113271945A (zh)	2018-12-20	2021-08-17	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
EP3897613A1 (en)	2018-12-21	2021-10-27	Novartis AG	Use of il-1beta binding antibodies
GB201901187D0 (en)	2019-01-29	2019-03-20	Autolus Ltd	Treatment of neurotoxicity and/or cytokine release syndrome
CN113329792B (zh)	2019-02-15	2024-06-28	诺华股份有限公司	取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220144807A1 (en)	2019-02-15	2022-05-12	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021116789A1 (en)	2019-12-09	2021-06-17	Novartis Ag	Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
CN115666704A (zh)	2019-12-13	2023-01-31	比奥拉治疗股份有限公司	用于将治疗剂递送至胃肠道的可摄取装置
CN115175937A (zh)	2019-12-20	2022-10-11	诺华股份有限公司	用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
WO2021257539A1 (en) *	2020-06-16	2021-12-23	Academia Sinica	ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
WO2022023907A1 (en)	2020-07-31	2022-02-03	Novartis Ag	Methods of selecting and treating patients at elevated risk of major adverse cardiac events
WO2022097060A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
WO2022167916A1 (en)	2021-02-03	2022-08-11	Novartis Ag	Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN117355323A (zh)	2021-05-24	2024-01-05	诺华股份有限公司	用于治疗骨关节炎的方法
CA3219360A1 (en)	2021-06-22	2022-12-29	Novartis Ag	Bispecific antibodies for use in treatment of hidradenitis suppurativa

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US534858A (en) *		1895-02-26		Workman s time-recorder
CA1172789A (en)	1980-09-25	1984-08-14	Hideo Kasahara	POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4935343A (en) *	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
DK590387A (da) *	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
EP0364778B1 (en)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Antibody against interleukin-1beta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en)	1989-06-07	1990-12-07	Clyde W. Shearman	Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) *	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP3714683B2 (ja) *	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/es active IP Right Grant
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/pt not_active IP Right Cessation
- 2001-08-20 AT AT01976118T patent/ATE396206T1/de active
- 2001-08-20 IL IL15446501A patent/IL154465A0/xx unknown
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/es active IP Right Grant
- 2001-08-20 ES ES01976118T patent/ES2305110T5/es not_active Expired - Lifetime
- 2001-08-20 PT PT01976118T patent/PT1313769E/pt unknown
- 2001-08-20 SK SK213-2003A patent/SK288089B6/sk not_active IP Right Cessation
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 EP EP01976118A patent/EP1313769B2/en not_active Expired - Lifetime
- 2001-08-20 DE DE60134148T patent/DE60134148D1/de not_active Expired - Lifetime
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/ja not_active Expired - Lifetime
- 2001-08-20 AU AU9549001A patent/AU9549001A/xx active Pending
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/da active
- 2001-08-20 PL PL360358A patent/PL212480B1/pl unknown
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/cs unknown
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/ru active Protection Beyond IP Right Term
- 2001-08-20 SI SI200130844T patent/SI1313769T2/sl unknown
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en active Active
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/ko active IP Right Grant
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/en active IP Right Grant
- 2001-08-20 HU HU0300806A patent/HU228159B1/hu active Protection Beyond IP Right Term
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/ko not_active Application Discontinuation
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/de active Pending
- 2001-08-20 CN CNB018145140A patent/CN100547003C/zh not_active Expired - Lifetime
- 2001-08-20 CA CA2420231A patent/CA2420231C/en not_active Expired - Lifetime
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/zh not_active IP Right Cessation
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/es unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/no not_active IP Right Cessation
2004
- 2004-04-29 HK HK04103018.8A patent/HK1061403A1/xx not_active IP Right Cessation
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/ja active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/el unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
2009
- 2009-11-24 NL NL300427C patent/NL300427I2/nl unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/fr unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/fr active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/el unknown
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Fee Related
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/no unknown
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/hu unknown
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/no unknown

Also Published As

Publication number	Publication date
NO2017052I2 (no)	2018-05-14
CA2420231A1 (en)	2002-02-28
EP1313769A2 (en)	2003-05-28
NO20030827D0 (no)	2003-02-21
BE2009C057I2 (no)	2021-01-28
US8273350B2 (en)	2012-09-25
CY2009019I1 (el)	2012-01-25
PL360358A1 (en)	2004-09-06
IL154465A0 (en)	2003-09-17
NL300427I1 (en)	2010-02-01
AU2001295490B2 (en)	2005-06-16
ATE396206T1 (de)	2008-06-15
FR09C0062I1 (no)	2010-08-01
LU91624I2 (fr)	2010-01-25
CA2420231C (en)	2011-04-26
ES2305110T3 (es)	2008-11-01
JP2004506448A (ja)	2004-03-04
CZ2003505A3 (cs)	2003-05-14
CY1108779T1 (el)	2012-01-25
KR100910789B1 (ko)	2009-08-04
NZ524199A (en)	2004-09-24
US20040063913A1 (en)	2004-04-01
HU228159B1 (en)	2013-01-28
ZA200301275B (en)	2004-04-02
DK1313769T4 (da)	2011-12-05
AU9549001A (en)	2002-03-04
KR20080056316A (ko)	2008-06-20
NO2012018I1 (no)	2012-12-10
MXPA03001590A (es)	2003-06-04
PE20020319A1 (es)	2002-06-11
GB0020685D0 (en)	2000-10-11
SI1313769T1 (sl)	2008-10-31
FR09C0062I2 (fr)	2010-12-31
ES2305110T5 (es)	2012-03-13
AR035581A1 (es)	2004-06-16
EP1313769B1 (en)	2008-05-21
JP4271936B2 (ja)	2009-06-03
MY130248A (en)	2007-06-29
NL300427I2 (en)	2010-02-01
SK2132003A3 (en)	2003-10-07
US20110256151A1 (en)	2011-10-20
CZ304470B6 (cs)	2014-05-21
NO332609B1 (no)	2012-11-19
ECSP034490A (es)	2003-03-31
SK288089B6 (sk)	2013-06-03
IL154465A (en)	2010-11-30
RU2286351C2 (ru)	2006-10-27
CN100547003C (zh)	2009-10-07
SI1313769T2 (sl)	2012-01-31
NZ534269A (en)	2006-04-28
US7993878B2 (en)	2011-08-09
CY2009019I2 (el)	2017-07-12
DE60134148D1 (de)	2008-07-03
BR0113420A (pt)	2003-07-29
EP1313769B2 (en)	2011-11-09
KR20030034140A (ko)	2003-05-01
CN1484652A (zh)	2004-03-24
BRPI0113420B8 (no)	2021-05-25
BRPI0113420B1 (pt)	2002-02-28
DE122009000078I1 (de)	2010-03-25
NO2012018I2 (no)	2012-11-21
US20090081732A1 (en)	2009-03-26
PT1313769E (pt)	2008-08-26
HUP0300806A3 (en)	2005-09-28
JP2008295456A (ja)	2008-12-11
DK1313769T3 (da)	2008-09-15
HUP0300806A2 (hu)	2003-12-29
WO2002016436A2 (en)	2002-02-28
HUS1300015I1 (hu)	2021-05-28
NO2017052I1 (no)	2017-10-11
LU91624I9 (no)	2018-11-19
TWI321568B (en)	2010-03-11
NO20030827L (no)	2003-04-14
US7446175B2 (en)	2008-11-04
PL212480B1 (pl)	2012-10-31
WO2002016436A3 (en)	2002-06-20

Publication	Publication Date	Title
HK1061403A1 (en)	2004-09-17	ANTIBODIES TO HUMAN IL-1ß
AU4835001A (en)	2001-09-24	Antibodies to human cd154
HK1050013A1 (zh)	2003-06-06	抗人IL-1β抗體
IL153721A0 (en)	2003-07-06	Antibodies to human mcp-1
GB0028926D0 (en)	2001-01-10	Improvements relating to skin prickers
IL213564A0 (en)	2011-07-31	Antibodies to vla-1
HUP0402247A3 (en)	2012-09-28	Antibodies to cd40
GB0103973D0 (en)	2001-04-04	Improvements relating to skin prickers
AU6269101A (en)	2001-12-17	Cosmetic preparation
AU7522401A (en)	2001-12-17	Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
GB2364338B (en)	2004-01-28	Improvements relating to construction
GB0028814D0 (en)	2001-01-10	Improvements relating to biosorbtion
AR028262A1 (es)	2003-04-30	Anticuerpos especificos de fap-alfa humanos
GB0024673D0 (en)	2000-11-22	Therapeutic antibodies
AU9481201A (en)	2002-04-08	Human nedd-1
GB0017139D0 (en)	2000-08-30	Human monoclonal antibodies
GB0016824D0 (en)	2000-08-30	Human monoclonal antibodies
GB0017107D0 (en)	2000-08-30	Improvements to velodromes
GB0005218D0 (en)	2000-04-26	Improvements relating to patient carrying structures
GB0025715D0 (en)	2000-12-06	Improvements relating to haribrushes
CA89697S (en)	2000-06-23	Walker
CA89698S (en)	2000-06-23	Walker
GB2362332B (en)	2003-12-03	Improvements relating to crackers
GB0005071D0 (en)	2000-04-26	Antibodies
GB0003527D0 (en)	2000-04-05	Antibodies

Legal Events

Date	Code	Title	Description
2021-09-03	PE	Patent expired	Effective date: 20210819